Search
Lyon Upgrades Tigermed Pharmaceuticals (03347) Target Price to HK$62.6, Maintains "Outperform" Rating
2025-08-07 /
Read about 0 minute
Author：小编
Tigermed Pharmaceuticals' share price has surged 83% year-to-date. Lyon Securities has released a research report forecasting a 7% to 9% growth in Tigermed's revenue from 2025 to 2027, accompanied by a net profit increase of approximately 30%. Consequently, Lyon has elevated the target price to HK$62.6 while retaining its "Outperform" rating. Lyon asserts that with the enhancement in the biotechnology financing landscape, Tigermed Pharmaceuticals' investment income is anticipated to surpass the clinical service fees derived from its core business. Furthermore, the company is projected to achieve single-digit sales growth in the second quarter, with new orders consistently on the rise.
-
C114 Communication Network -
Communication Home
7 X 24 Track global technological trends
